Arcturus Therapeutics (ARCT) Tops Q3 EPS by 48c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($1.33), $0.48 better than the analyst estimate of ($1.81). Revenue for the quarter came in at $13.4 million versus the consensus estimate of $3.42 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Franklin BSP Realty Trust (FBRT) Reiterated at Market Outperform by Citizens on Q1 Results
• BofA sees semiconductor pullback as healthy reset before rally